Phreesia, Inc. (PHR)
NYSE: PHR · Real-Time Price · USD
12.26
-0.30 (-2.39%)
At close: Nov 18, 2026, 4:00 PM EST
12.39
+0.13 (1.06%)
Pre-market: Nov 19, 2026, 4:32 AM EST
Phreesia Revenue
Phreesia had revenue of $129.46M in the quarter ending July 31, 2026, with 10.41% growth. This brings the company's total for the last twelve months to $507.79M, up 12.93% year-over-year. In the fiscal year ending January 31, 2026, Phreesia had annual revenue of $480.59M with 14.48% growth. That makes Phreesia the 11,187th largest company in the world by revenue and 2,281st in the United States.
Revenue (ttm)
$507.79M
Revenue Growth
+12.93%
P/S Ratio
1.50
Revenue / Employee
$283,842
Employees
1,789
Market Cap
760.99M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jan 31, 2026 | 480.59M | 60.78M | 14.48% |
| Jan 31, 2025 | 419.81M | 63.51M | 17.83% |
| Jan 31, 2024 | 356.30M | 75.39M | 26.84% |
| Jan 31, 2023 | 280.91M | 67.68M | 31.74% |
| Jan 31, 2022 | 213.23M | 64.56M | 43.42% |
| Jan 31, 2021 | 148.68M | 23.89M | 19.15% |
| Jan 31, 2020 | 124.78M | 24.90M | 24.92% |
| Jan 31, 2019 | 99.89M | 20.06M | 25.12% |
| Jan 31, 2018 | 79.83M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Teladoc Health | 2.47B |
| Evolent Health | 2.34B |
| Omnicell | 1.24B |
| Claritev | 1.02B |
| GoodRx Holdings | 785.23M |
| Certara | 425.76M |
| Omada Health | 333.04M |
| HealthStream | 327.95M |
PHR News
- 8 days ago - JPMorgan downgrades Phreesia to Underweight on slowing sales - TheFly
- 8 days ago - Phreesia downgraded to Underweight from Neutral at JPMorgan - TheFly
- 13 days ago - Phreesia Sets Release Date for Fiscal Third Quarter 2027 Results - Business Wire
- 15 days ago - Phreesia's Sophia Wagner Named to Becker's 2026 List of Health IT & Revenue Cycle Up-and-Comers - Business Wire
- 5 weeks ago - Phreesia price target raised to $11 from $10 at Barclays - TheFly
- 6 weeks ago - Phreesia's Michael Rasbury Named to Becker's 2026 List of Rising Stars: Healthcare Leaders Under 40 - Business Wire
- 7 weeks ago - Phreesia Named to TIME's 2026 List of the World's Top HealthTech Companies - Business Wire
- 7 weeks ago - Phreesia management to meet with KeyBanc - TheFly